The Latest Breaking News from Johnson & Johnson (

Despite ongoing legal battles related to its talc products, Johnson Johnson (NYSE:JNJ) stock has climbed over 23% year-to-date.

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson Johnson's (NYSE:JNJ) Inlexzo (gemcitabine intravesical system) as a new treatment approach for certain types of bladder cancer patients who need additional options following unsuccessful BCG therapy and for patients refusing or ineligible for bladder removal surgery (radical cystectomy).

As the healthcare sector lags broader markets, AbbVie’s innovation in immunology and Johnson & Johnson’s MedTech expansion make these dividend giants standout bargains at below-market valuations

Health care saw some of the worst losses this year. But as the calendar turned to August, it's been leading the market higher. This ETF provides exposure.

Bridgewater Associates, the world's largest hedge fund, has completely liquidated its holdings in all U.S.-listed Chinese companies, a dramatic reversal that marks the firm's most significant strategic pivot under its new post-Ray Dalio leadership.

Procter & Gamble, PepsiCo, and Johnson & Johnson stand out as dividend growth leaders with upside potential into year-end

Johnson & Johnson's strategic shift to a focused pharma and medtech model is fueling growth through a powerful drug pipeline and key acquisitions.

Johnson Johnson (NYSE:JNJ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs proposed by the Trump administration.

Volatility is back in the markets, and jobs data points to a weakening labor market. Is it time to get defensive? Consider these 3 dividend stocks for income.